Research in brief

ABSTRACT

Full-dose anticoagulation in COVID-19 patients Full-dose anticoagulation lowers the risk of blood-clotting complications compared with standard-dose prophylactic anticoagulation, according to a clinical trial in critically ill COVID-19 patients across the USA. The study did not include a control group, and the time from symptom onset to starting antiviral therapy varied among the patients. For more on baseline SARS-CoV-2 antigen levels and illness severity see Ann Intern Med 2022;published online Aug 30. https//doi.org/10.7326/m22-0924 For more on full-dose anticoagulation and COVID-19 see Circulation 2022;published online Aug 29. https//doi.org/10.1161/circulationaha.122.061533 For more on COVID-19 antiviral combinations see J Infect 2022;published online July 31. https//doi.org/10.1016/j.jinf.2022.07.023 For more on dolutegravir-based ART and pregnancy see N Engl J Med 2022;387 799–809 For more on HBV and HDV treatment see Gut 2022;published online Aug 17. https//doi.org/10.1136/gutjnl-2022-327216 For more on tecovirimat and monkeypox see JAMA 2022;published online Aug 22. https//doi.org/10.1001/jama.2022.15336 For more on an injectable tuberculosis treatment see Nat Commun 2022;13 4455